Agios Pharmaceuticals (AGIO) Consolidated Net Income (2012 - 2026)

Agios Pharmaceuticals has reported Consolidated Net Income for 14 years, with the latest figure at -$99.2 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income fell 9.6% year-over-year to -$99.2 million; the trailing twelve-month figure through Mar 2026 stood at -$423.2 million (down 163.82% YoY), and the FY2025 full-year result was -$412.8 million, down 161.27% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$99.2 million, up from -$108.0 million in the prior quarter.
• The five-year high for Consolidated Net Income was $947.9 million in Q3 2024, with the low at -$112.5 million in Q2 2025.
• Historically, Consolidated Net Income has averaged -$15.3 million across 4 years, with a median of -$95.9 million in 2023.
• Annual changes were most pronounced in 2024 — Consolidated Net Income jumped 1137.97% — and 2025, when it sank 110.91%.
• Agios Pharmaceuticals' Consolidated Net Income stood at -$95.9 million in 2023, then retreated by 0.61% to -$96.5 million in 2024, then dropped by 11.93% to -$108.0 million in 2025, then rose by 8.15% to -$99.2 million in 2026.
• The last three Consolidated Net Income figures came in at -$99.2 million (Q1 2026), -$108.0 million (Q4 2025), and -$103.4 million (Q3 2025), per Business Quant data.